Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Molecules. 2021 Jan 16;26(2):459. doi: 10.3390/molecules26020459.
Ilaprazole is a proton pump inhibitor used to treat digestive diseases. In this study, blood samples were collected after oral administration of ilaprazole and prepared by liquid-liquid extraction. The metabolites of ilaprazole were detected by liquid chromatography-high-resolution mass spectrometry (LC-HRMS) and LC-MS. A total of twelve in vivo metabolites were detected in rat plasma and six new metabolites of ilaprazole, including one reductive metabolite with sulfide (), two hydroxylated metabolites with sulfoxide ( and ), and three oxidative metabolites with sulfone (, , and ), were identified. The possible metabolic pathways of ilaprazole and the fragmentation behaviors of its metabolites were elucidated. The result of the in silico prediction indicates that all the new metabolites showed the potential ability to inhibit H/K-ATPase activity.
艾拉普拉唑是一种质子泵抑制剂，用于治疗消化系统疾病。在这项研究中，给大鼠口服艾拉普拉唑后采集血样，采用液液萃取法进行处理。采用液相色谱-高分辨质谱（LC-HRMS）和 LC-MS 法检测艾拉普拉唑的代谢物。在大鼠血浆中检测到 12 种体内代谢物，鉴定出艾拉普拉唑的 6 种新代谢物，包括一个带有硫醚（）的还原代谢物、两个带有亚砜（和）的羟基化代谢物和三个带有砜（、和）的氧化代谢物。阐明了艾拉普拉唑的可能代谢途径及其代谢物的裂解行为。计算机预测的结果表明，所有新代谢物均显示出抑制 H/K-ATP 酶活性的潜力。
